A revolutionary cystic fibrosis medication is offering hope to those unable to afford it due to a loophole in patent law. Produced generically in Bangladesh, this version provides a more accessible option for families worldwide.
Josua Lottering, along with his mother, embarked on a journey from South Africa to Bangladesh to acquire this essential drug. Cystic fibrosis has significantly compromised Josua’s lung function, making travel an arduous task.
Trikafta, the original drug developed by Vertex Pharmaceuticals in Boston, dramatically improves the lives of those with cystic fibrosis. Priced at around $346,000 annually in the U.S., it has generated $49 billion in revenue since 2019. Vertex holds a monopoly on this treatment, making it inaccessible in many lower-income nations.
The situation changed when a company in Bangladesh reverse engineered Trikafta to create a generic version called Triko. Using a loophole in patent law, they sell Triko at a much lower price than the original. This development has enabled patients like Josua to hope for an improved quality of life.
Last week, Josua and other patients traveled to Dhaka to purchase Triko from Beximco Pharmaceuticals. Their journey underscores the crucial role of accessible medicine for patient survival and quality of life.
Cancer Death Rates Decline in the U.S., But Disparities Remain 
Rising Heat Poses Threat Across U.S., Authorities Warn 
COVID-19 Vaccine Study Highlights Effectiveness Amid Controversy 
Life Inside Biocontainment and Updates on Covid-19 Vaccine Policies 
Extreme Heat Risk Spreads Across the U.S. 
Efforts to Address Hospice Fraud and Strengthen Program Integrity